{{Rsnum
|rsid=2193225
|Gene=NRXN1
|Chromosome=2
|position=50852344
|Orientation=minus
|GMAF=0.326
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NRXN1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 11.5 | 55.8 | 32.7
| HCB | 71.5 | 26.3 | 2.2
| JPT | 62.8 | 32.7 | 4.4
| YRI | 76.2 | 22.4 | 1.4
| ASW | 54.4 | 43.9 | 1.8
| CHB | 71.5 | 26.3 | 2.2
| CHD | 70.4 | 25.9 | 3.7
| GIH | 48.5 | 38.6 | 12.9
| LWK | 71.8 | 24.5 | 3.6
| MEX | 43.1 | 36.2 | 20.7
| MKK | 50.0 | 42.3 | 7.7
| TSI | 25.5 | 51.0 | 23.5
| HapMapRevision=28
}}[[rs2193225]] has been reported to be associated with increased risk for nicotine dependence. {{PMID|18270208|OA=1
}}

{{PharmGKB
|RSID=rs2193225
|Name_s=
|Gene_s=NRXN1
|Feature=
|Evidence=PubMed ID:18270208
|Annotation=A study on 2037 individuals from 602 nuclear families of African-American or European-American origin found a significant associations of this SNP in the NRXN1 gene with smoking quantity, the heaviness of smoking index and the Fagerstr?m test for nicotine dependence in the European-American sample.
|Drugs=nicotine
|Drug Classes=
|Diseases=Tobacco Use Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA162316626
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2193225
|overall_frequency_n=48
|overall_frequency_d=128
|overall_frequency=0.375
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=40
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}